Ani Pharmaceuticals (ANIP) Cash from Investing Activities (2010 - 2026)

Ani Pharmaceuticals has disclosed Cash from Investing Activities across 17 years of filings, most recently posting -$3.1 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities rose 55.8% year-over-year to -$3.1 million; the TTM figure through Jun 2026 stood at -$21.9 million (up 94.97% YoY), while the FY2025 annual figure was -$34.3 million, up 91.52% from the prior year.
• Cash from Investing Activities came in at -$3.1 million for Q2 2026 at Ani Pharmaceuticals, up from -$11.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $8.9 million in Q1 2024 to a low of -$398.5 million in Q3 2024.
• Average Cash from Investing Activities over 5 years is -$27.1 million, with a median of -$4.7 million recorded in 2023.
• The largest YoY upside for Cash from Investing Activities was 479.64% in 2024 against a maximum downside of 8652.95% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$3.1 million in 2022, then tumbled by 52.1% to -$4.8 million in 2023, then slumped by 123.5% to -$10.7 million in 2024, then soared by 86.86% to -$1.4 million in 2025, then plunged by 117.68% to -$3.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$3.1 million in Q2 2026, -$11.3 million in Q1 2026, and -$1.4 million in Q4 2025.